GLP-1 Market Monitor
$79.0bnAnnual market size
9.17%Forecast annual growth (CAGR)2025–2035
Active companies
Eli Lilly
Pharmaceutical manufacturer 🇺🇸, United States
Eli Lilly develops and manufactures medicines for diabetes, obesity, cancer and other diseases. Its portfolio includes Mounjaro and Zepbound (tirzepatide) and Trulicity (dulaglutide). Its activity in this market spans medicine sales, investment in emerging drug developers and the development of new treatments.
Market Cap
$1.1tn
As of 2026-09-14 · USD · Recorded monthly observations
Ticker Mentions
11
Last 12 months
Deal Activity
1
Last 12 months
What Is Happening at Eli Lilly
- A pipeline setback: Lilly stopped development of an early obesity candidate after it fell short of the company’s criteria.
- Growing competition in oral treatments: Recent reporting tracks Foundayo’s prescription uptake alongside Novo Nordisk’s Wegovy pill.
- Investment beyond GLP-1: Lilly participated in Superluminal’s $60m financing to advance an obesity program targeting MC4R.
Mentioned In
Latest Deals
People
Daniel Skovronsky
Daniel Skovronsky leads research and development at Eli Lilly and serves as president of Lilly Research Laboratories.
David Ricks
David Ricks leads Eli Lilly as chair and chief executive officer.
Live Ticker
Fierce Pharma Reports Questions Over Savings From Lilly’s US Drug-Pricing Deal
Fierce Pharma reports that newly released agreement documents have prompted questions about how much Lilly’s US pricing deal will save on GLP-1 obesity medicines.
Mentions:Eli Lilly
Eli LillyNovo Reports Greater Weight Loss Than a Tested Dose of Lilly’s Diabetes Drug
Novo Nordisk says its experimental CagriSema injection produced more weight loss than a tested dose of Lilly’s tirzepatide in adults with type 2 diabetes. The comparison does not cover every available dose.
Lilly Starts Construction of $6.5 Billion Houston Drug Plant
Lilly says construction has begun on a $6.5 billion Houston factory to make ingredients for Foundayo and other medicines. The factory is intended to expand production capacity; it is not yet operating.
Mentions:Eli Lilly
Eli LillyFierce Biotech Reports Lilly Has Stopped Developing an Experimental Obesity Drug
Lilly has stopped work on the experimental obesity drug LY4064912, Fierce Biotech reported. The decision concerns an early research project, rather than Lilly’s approved weight-loss medicines.
Mentions:Eli Lilly
Eli LillyFierce Pharma Reports Record Weekly Prescriptions for Two Weight-Loss Pills
Fierce Pharma reported record weekly prescriptions for Novo’s Wegovy pill and Lilly’s Foundayo. The figures track prescriptions, including refills, rather than new patients or comparative treatment results.
Superluminal Announces $60 Million to Advance an Experimental Obesity Drug
Investors led by BVF Partners are providing Superluminal with $60 million to advance an experimental obesity treatment. Lilly is participating as an investor in this funding round.
